The People's Perspective on Medicine

Could Heart Drug Combo Be Hurting People with AFib?

The heart drug combo of the anti-clotting medicine Pradaxa with cholesterol-lowering agents simvastatin or lovastatin could lead to dangerous bleeding.

Patients with an irregular heart rhythm called atrial fibrillation (AFib) are frequently prescribed an anticoagulant to prevent blood clots. But adding another common cardiovascular drug might be dangerous. What is this risky heart drug combo?

Anticoaguants for AFib:

One of the more popular medications for clot prevention is called Pradaxa, known generically as dabigatran. It is important for people with AFib to be protected against clots, because their blood doesn’t circulate smoothly through the heart as it should. If it gets trapped in eddies, it might clot unless the person is taking an anticoagulant. From the heart, a clot could travel to the brain and cause a stroke, or get stuck in the lung as a pulmonary embolism.

Watch Out for This Heart Drug Combo:

New research shows that when dabigatran is combined with a cholesterol-lowering drug such as simvastatin or lovastatin, patients have an increased risk for hemorrhage. These statins increase blood levels of dabigatran, and that raises the chance of excessive bleeding.

One way to avoid this problem would be to use a different statin to control cholesterol. Agents such as atorvastatin or rosuvastatin do not appear to interact with Pradaxa and increase the likelihood of hemorrhage. Accordingly, either Crestor or Lipitor would be better in a Pradaxa heart drug combo.

CMAJ, online November 21, 2016 

Previous research has shown that people taking Pradaxa for AFib need to stop taking it before surgery or biopsy. You can read what we wrote about that problem here.

Fortunately, there is a medication to reverse bleeding due to Pradaxa. But unless a person is already hospitalized, it might be difficult to administer it quickly enough.

Rate this article
star-fullstar-emptystar-fullstar-emptystar-fullstar-emptystar-fullstar-emptystar-fullstar-emptystar-fullstar-emptystar-fullstar-emptystar-fullstar-emptystar-fullstar-emptystar-fullstar-empty
4.5- 12 ratings
About the Author
Terry Graedon, PhD, is a medical anthropologist and co-host of The People’s Pharmacy radio show, co-author of The People’s Pharmacy syndicated newspaper columns and numerous books, and co-founder of The People’s Pharmacy website. Terry taught in the Duke University School of Nursing and was an adjunct assistant professor in the Department of Anthropology. She is a Fellow of the Society of Applied Anthropology. Terry is one of the country's leading authorities on the science behind folk remedies. .
Cholesterol Control & Heart Health
$2.00

Download the guide: Heart disease is still a top killer, and high cholesterol is an important risk factor. 8 pages on the pros and cons of statins as well as non-statin drugs for cholesterol.

Cholesterol Control & Heart Health
Join over 150,000 Subscribers at The People's Pharmacy

We're empowering you to make wise decisions about your own health, by providing you with essential health information about both medical and alternative treatment options.

Showing 2 comments
Comments
Add your comment

I took the antibiotic Cipro for bronchitis around 1996. Shortly thereafter I noticed a squishy feeling in my chest. The doctor did tests and said I had atrial fibrillation. I was put on several drugs, which didn’t help. After reading the side effects, I decided not to take them anymore. I started taking natokinase, and some whole food supplements specifically designed for the condition. I’ve been on that course for 20 years. I still have an irregular heartbeat, but I don’t get that squishy feeling in my chest. I’ve had no stroke or heart attack. I’ve read that the heart is the most responsive organ in the body to top nutrition. A few years ago I read a study on Ciprio and learned that it can and will cause heart damage. I wouldn’t be surprised it that is what happened to me.

Any problems associated with Eliquis?

* Be nice, and don't over share. View comment policy^